MAP2K7 and plexiform neurofibroma: Rigorous monitoring is recommended for all pediatric patients with NF1 and symptomatic, inoperable plexiform neurofibromas who are treated with MEK inhibitors, to ensure appropriate management of side effects and optimization of dosing.